Adam David Durbin

The paper identifies a core regulatory circuit in rhabdomyosarcoma and shows that targeting two co-activators synergistically inhibits tumor growth.

The paper develops ALTitude, a machine learning model to predict ALT status from whole genome sequencing data, identifies SMARCAL1 as a therapeutic target in ALT-driven cancers.

This study identifies specific developmental epigenomic states that enable ZFTA-RELA-driven ependymoma formation and reveals how these states shape tumor progression.

This study shows that inhibiting KAT6A/B with PF-9363 enhances retinoid efficacy and improves GD2-targeted immunotherapy in neuroblastoma.

This study identifies PRMT5's role in promoting EMT in neuroblastoma by regulating EGFR and AKT pathways, leading to NFκB activation and tumor growth.